TI
CLDX icon

Turner Investments’s Celldex Therapeutics CLDX Stock Holding History

Turner Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,200
Closed -$502K – 270
2015
Q1 		$502K Buy
+1,200
New +$429K 0.09% 225

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Turner Investments's CLDX Position: Q2 2015 in Review

Turner Investments sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 1,200 shares — an estimated $502K sold.

Turner Investments first reported a position in CLDX in Q1 2015 and held it in 1 quarter. The position peaked at $502K in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

  • Turner Investments reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Turner Investments sold 1,200 Celldex Therapeutics shares in Q2 2015, an estimated $502K.
  • Turner Investments first reported a position in Celldex Therapeutics in Q1 2015 and held it in 1 quarter.
  • Turner Investments's Celldex Therapeutics position peaked at $502K in Q1 2015.
  • 186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Turner Investments's 13F filing for Q2 2015, filed 12 Aug 2015.